Calgary, Alberta
May 15, 2007
SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company
developing insulin and other metabolic and
cardiovascular protein-based pharmaceuticals and a series of
non-pharmaceutical products, today announced that its President
and CEO, Andrew Baum, was named as an officer of the
Biotechnology Industry Organization (BIO) Board of Directors for
the 2007/2008 year. In his new role Mr. Baum will serve as
Secretary of the BIO Board as well as Vice Chair, Food &
Agriculture. Mr. Baum will continue to fulfill his existing role
as a Director of the Board and Chair of the Food & Agriculture
Committee.
"I would like to congratulate
Andrew Baum on his recent appointment as an officer of the Board
of Directors of BIO," said Richard Smith, Chairman of the Board
of Directors of SemBioSys. "While the membership of BIO will
gain the benefit of Andrew's enthusiasm and extensive knowledge
of the biotechnology industry, SemBioSys will in turn gain great
benefit from the experience and network developed by Andrew as
we continue to advance our pipeline of pharmaceutical and
non-pharmaceutical products."
"I welcome the opportunity to work
with other members of the biotechnology industry toward the
development and advancement of new life-saving and
life-enhancing drugs and diagnostics," said Andrew Baum. "In
particular, I am looking forward to contributing to the
knowledge and awareness of food and agriculture to the biotech
industry from the unique perspective as an executive of a
company that integrates agricultural and
medical biotechnology."
BIO represents more than 1,100
biotechnology companies, academic institutions, state and
provincial biotechnology centers and related organizations
across the United States, Canada and 30 other nations. BIO
members are involved in the research and development of
healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the annual BIO
International Convention, the global event for
biotechnology.
Calgary, Alberta-based SemBioSys Genetics Inc. is a
biotechnology company developing insulin and other protein-based
pharmaceuticals for metabolic and cardiovascular diseases. The
Company's lead candidate is recombinant human insulin produced
in the plant host safflower, to serve the rapidly expanding
global diabetes market and to supply insulin for inhalation and
other alternative insulin delivery technologies. The Company's
other protein-based pharmaceutical candidate is a cardiovascular
drug called Apo AI. SemBioSys is also developing a series of
non-pharmaceutical products addressing animal and aquaculture
health, nutritional oils and human topical markets. |
|
